Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adamas Pharmaceuticals Inc.

www.adamaspharma.com

Latest From Adamas Pharmaceuticals Inc.

Sandoz Will Wait A Decade On Amantadine

Sandoz will be able to launch a generic of Adamas’ amantadine-based Gocovri brand in the US from March 2030. But a patent-litigation settlement permits an earlier entry if sales of the dyskinesia brand decline.

Intellectual Property Neurology

Acorda Restructures, Cuts Jobs By 25% With No Deals, Big Debt On The Horizon

Acorda is cutting jobs to save $21m annually and otherwise lowering expenses for a total of $60m in reduced costs in 2020 to focus on marketing Inbrija, but looming overhead is $345m in debt due in 2021. Meanwhile, ex-US partners and company buyers appear nowhere in sight.

Business Strategies Companies

Pharma Sourcing And Procurement: The New Strategy Of Spend

Just what does a strategic approach to sourcing and procurement mean for today’s biopharma enterprise? In Vivo talks to the practice leaders at two diversely representative companies – Adamas Pharmaceuticals and Roivant Sciences – to identify four essential characteristics of “best in class” purchasing performance: (1) Think big – be strategic. (2) Buy better – add value.  (3) Work fast – spend forward. (4) Reach out earn the business.

Business Strategies Growth

Pipeline Watch: Phase III Starts With Enzastaurin, Sparsentan And Abaloparatide

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • NeuroMolecular Pharmaceuticals Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Adamas Pharmaceuticals Inc.
  • Senior Management
  • Neil McFarlane, CEO
    Merriweather G Alfred, CFO
    Vijay Shreedhar, PhD, COO
  • Contact Info
  • Adamas Pharmaceuticals Inc.
    Phone: (510) 450-3500
    2200 Powell St.
    Ste. 750
    Emeryville, CA 94608
    USA
UsernamePublicRestriction

Register